ArticleAdvances in radiation oncology2026
Early Salivary Gland Shrinkage Is Associated With an Increased Risk of Acute Xerostomia in Head and Neck Cancer Radiation Therapy.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: To investigate the relationship between geometric and dosimetric characteristics of salivary glands and acute xerostomia during or shortly after radiation therapy in patients with head and neck cancer (HNC). Methods and Materials: We used an Automated Watchdog in Adaptive Radiotherapy Environment (AWARE) program to monitor changes in tumor and organ-at-risk using weekly cone beam computed tomography (CT) images for patients with HNC. Gross tumor volume and organ-at-risk contours were propagated from the planning CT to the weekly cone beam CT using deformable registration and reviewed by clinical users. This study analyzed 165 evaluable patients with AWARE-HNC treated between 2021 and 2024. The National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 was employed to grade toxicities. Acute xerostomia was defined as grade ≥2, occurring during or within 3 months after radiation therapy completion. We compared weekly salivary (parotid and submandibular) gland shrinkage and radiation doses between patients with and without acute xerostomia. Results: Of the 165 patients with HNC, 66 (40.0%) developed acute xerostomia. Patients with acute xerostomia exhibited significantly larger parotid gland shrinkage in the second and third weeks and submandibular gland shrinkage in the second week (15.4%, 21.0%, and 13.1%, respectively; Conclusions: Increased mean doses to the ipsilateral parotid and submandibular glands were associated with larger salivary gland shrinkage during radiation therapy and a significantly higher risk of acute xerostomia. This early signal could trigger adaptive replanning promptly. Cone-down and adaptive techniques can reduce the salivary gland dose, helping mitigate the risk of acute xerostomia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.